Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease

Itaru Iwama; Masashi Yoshida; Ayako Miyazawa; Tomoko Hara; Ryusuke Nambu

doi:10.1093/ibd/izae078

Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease

Inflamm Bowel Dis. 2024 Jul 3;30(7):1220-1222. doi: 10.1093/ibd/izae078.

Authors

Itaru Iwama¹, Masashi Yoshida¹, Ayako Miyazawa¹, Tomoko Hara¹, Ryusuke Nambu¹

Affiliation

¹ Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.

No abstract available

Keywords: steroid-free clinical remission; ustekinumab; very early-onset inflammatory bowel disease.

Plain language summary

We observed efficacy and safety of ustekinumab in very early-onset inflammatory bowel disease, which has not been previously reported. Clinical remission at 52% was 75%, often persisting beyond 2 years. Further studies including larger numbers of cases are needed to confirm this observation.

Publication types

Letter
Case Reports

MeSH terms

Age of Onset
Humans
Inflammatory Bowel Diseases* / drug therapy
Remission Induction*
Treatment Outcome
Ustekinumab* / therapeutic use

Substances

Ustekinumab